Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response

Abstract Objective JDM is a rare chronic immune-mediated inflammatory disease with a predominant role for type I IFN responses. We aimed to determine the potential of Siglec-1 expression on monocytes as a novel IFN-inducible biomarker for disease activity monitoring and prediction of treatment response in patients with JDM. Methods Siglec-1 was measured by flow cytometry on circulating monocytes of 21 newly diagnosed JDM patients before start of treatment and, for 10 of these, also during follow-up. The expression levels of five type I IFN-stimulated genes, MX1, IFI44, IFI44L, LY6E and IFIT3, were measured by RT-qPCR to determine the IFN signature and calculate an IFN score. IFN-inducible plasma proteins CXCL10 and galectin-9 were measured by multiplex immunoassay. Results Siglec-1 and IFN score were increased in JDM patients compared with controls and correlated with clinical disease activity. Stratification of patients by Siglec-1 expression at diagnosis identified those with high Siglec-1 expression as having a higher risk of requiring treatment intensification within the first 3 months after diagnosis (55% vs 0% of patients, P = 0.01). Siglec-1 expression strongly correlated with plasma levels of previously validated biomarkers CXCL10 (rs = 0.81, P < 0.0001) and galectin-9 (rs = 0.83, P < 0.0001), and was superior to the IFN score in predicting treatment response (area under the curve 0.87 vs 0.53, P = 0.01). Conclusion Siglec-1 on monocytes is a novel IFN-inducible biomarker in JDM that correlates with clinical disease activity and identifies patients at risk for a suboptimal treatment response. Further studies are required to validate these findings and their clinical potential.

[1]  C. Günther,et al.  Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? , 2020, Rheumatology.

[2]  Q. Lu,et al.  Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases , 2020, Clinical Reviews in Allergy & Immunology.

[3]  Y. Huang,et al.  Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies , 2020, Arthritis Research & Therapy.

[4]  S. Kamphuis,et al.  Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis , 2020, Arthritis & Rheumatology (Hoboken, N.j.).

[5]  C. Minetti,et al.  Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features , 2019, Arthritis & rheumatology.

[6]  S. Kamphuis,et al.  Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation , 2019, Arthritis & rheumatology.

[7]  L. Wedderburn,et al.  Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools , 2018, Front. Immunol..

[8]  W. Stenzel,et al.  JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis , 2018, Brain : a journal of neurology.

[9]  J. Todd,et al.  The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus , 2018, bioRxiv.

[10]  P. Lachenbruch,et al.  EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report , 2017, RMD Open.

[11]  N. Wulffraat,et al.  Consensus-based recommendations for the management of juvenile dermatomyositis , 2016, Annals of the rheumatic diseases.

[12]  Andreas Radbruch,et al.  SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome , 2016, RMD Open.

[13]  T. Niewold,et al.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases. , 2016, Gene.

[14]  T. Southwood,et al.  Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated , 2015, Arthritis & rheumatology.

[15]  A. Somani,et al.  The role of type I interferons and other cytokines in dermatomyositis. , 2015, Cytokine.

[16]  R. Zhong,et al.  Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis. , 2014, Rheumatology.

[17]  S. Greenberg,et al.  A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients , 2013, Annals of the rheumatic diseases.

[18]  Chiang-Ching Huang,et al.  Lack of Achievement of a Full Score on the Childhood Myositis Assessment Scale by Healthy Four‐Year‐Olds and Those Recovering From Juvenile Dermatomyositis , 2013, Arthritis care & research.

[19]  X. Montalban,et al.  SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis , 2013, Multiple sclerosis.

[20]  G. Mullen,et al.  Sialoadhesin – a macrophage‐restricted marker of immunoregulation and inflammation , 2013, Immunology.

[21]  J. Malley,et al.  The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies , 2013, Medicine.

[22]  N. Wulffraat,et al.  The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis , 2012, Annals of the rheumatic diseases.

[23]  H. Drexhage,et al.  Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression , 2012, Annals of the rheumatic diseases.

[24]  S. Amin,et al.  Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. , 2012, Arthritis and rheumatism.

[25]  S. Kong,et al.  Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis , 2011, Genes and Immunity.

[26]  S. Amin,et al.  Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. , 2009, Arthritis and rheumatism.

[27]  L. Pulliam,et al.  Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity , 2008, PloS one.

[28]  S. Kong,et al.  Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. , 2007, Arthritis and rheumatism.

[29]  P. Lachenbruch,et al.  The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. , 2007, Rheumatology.

[30]  R. Lafyatis,et al.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. , 2007, Arthritis and rheumatism.

[31]  P. Gregersen,et al.  An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.

[32]  L. Pachman,et al.  MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. , 2006, Clinical immunology.

[33]  B. Feldman,et al.  An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). , 2006, Rheumatology.

[34]  W. Kuis,et al.  Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. , 2005, Journal of immunological methods.

[35]  P. Crocker,et al.  The potential role of sialoadhesin as a macrophage recognition molecule in health and disease , 1997, Glycoconjugate Journal.

[36]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. K. van den Berg,et al.  Cutting Edge: CD43 Functions as a T Cell Counterreceptor for the Macrophage Adhesion Receptor Sialoadhesin (Siglec-1) , 2001, The Journal of Immunology.

[38]  D. Jackson,et al.  Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. , 2001, Blood.

[39]  À. Franch,et al.  Immunohistochemical study of lymphoid tissues in adjuvant arthritis (AA) by image analysis; relationship with synovial lesions , 2000, Clinical and experimental immunology.

[40]  P. Lachenbruch,et al.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. , 1997, Arthritis and rheumatism.

[41]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[42]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[43]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .

[44]  S. Wolfram.  [On dermatomyositis]. , 1960, Wiener medizinische Wochenschrift.